Event Date/Time: Feb 12, 2012
End Date/Time: Feb 17, 2012
Feb 12, 2012
Early Registration Date:
Dec 12, 2011
Although altered glucose metabolism was first noted as a characteristic of tumor cells by Otto Warburg in the 1920s, the molecular underpinning for this observation did not begin to be appreciated fully until the past decade. This area has exploded over the last five years with the identification of extensive interactions of genuine tumor suppressor genes and oncogenes with metabolic control. The increased biosynthetic needs of tumor cells demand a reprogramming of cellular metabolism, which also creates increased energy demands and makes tumor cells more vulnerable to interventions targeting their metabolism. The goal of the Keystone Symposia meeting on Cancer and Metabolism is to bring together leaders in the fields of cancer and metabolic control with those studying the signaling pathways linking and governing each. The latest discoveries will be discussed as well as how this knowledge can be exploited to design future cancer therapeutics. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Advances in Hypoxic Signaling: From Bench to Bedside, which will share a keynote address and a plenary session with this meeting.
This meeting is held jointly with the Keystone Symposia meeting "Advances in Hypoxic Signaling: From Bench to Bedside."
Registering for one meeting in a set of joint meetings enables participation in sessions of the other, pending space availability.
Abstract & scholarship - October 13, 2011
Late-breaking abstract - November 14, 2011